Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Soligenix Inc (NASDAQ: SNGX)

$2.32 USD -$0.03 (-1.28%)
Last Price $2.32
Net Change $-0.03 (-1.28%)
Bid $0
Ask Price $0
Open Price $2.28
Previous Close Price $2.35
High Price $2.38
Low Price $2.28
Number of Trades 182
Volume 41,100
Fifty Two Week High $8.9 (2016-06-07)
Fifty Two Week Low $1.9 (2017-02-24)
Average Daily Volume 423,011
Share Outstanding 5,670 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $1.81
Recent Earnings $
Annual EPS $-1.12
Last Quarter EPS $
Market Capitalization $0.01B
Insider Shareholders % 0.0609%
Annual Revenue $0B
No. Shares Outstanding 5,670
Inst. Shareholder % 8.75%
Annual Net Income $-0B
TTM Net Profit Margin $-41.75
1-Year Return -66.86%
3-Year Return -87.25%
5-Year Return -22.67%
5-Year Revenue Growth 36.42%
5-Year Earnings Growth -37.27%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD 1.81%
Dividends per Share $
Stock Split Ratio 1-10
Beta 2.29
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ' (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.

SNGX News & Stock Updates